STRENSIQ DIN 02444631
Status: Marketed
Holder: ALEXION PHARMA GMBH
Health Canada record
| Active ingredient(s) | ASFOTASE ALFA 40 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | A16AB13 ASFOTASE ALFA |
|---|
| Original market date | 01-Jun-2016 |
|---|
| Current status date | 01-Jun-2016 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Alexion Pharma Canada Corp — licence 101731, currently licensed, last inspection rating C (2026-02-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ASFOTASE ALFA
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02444607 | STRENSIQ | ALEXION PHARMA GMBH | Solution | ASFOTASE ALFA 40 MG | Approved |
| 02444615 | STRENSIQ | ALEXION PHARMA GMBH | Solution | ASFOTASE ALFA 40 MG | Marketed |
| 02444623 | STRENSIQ | ALEXION PHARMA GMBH | Solution | ASFOTASE ALFA 40 MG | Marketed |
| 02444658 | STRENSIQ | ALEXION PHARMA GMBH | Solution | ASFOTASE ALFA 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 17204 | 2015-08-14 | New Drug Submission (NDS) | |
Request a quote for STRENSIQ
How to read a Canadian DIN record